Identification of PLCG2 activators for the treatment of Alzheimer’s disease
Brent Clayton, Steven M Massey, Daniel E Beck, Karson S Putt, Tada Utsuki, Ramya Visvanathan, Andrew D Mesecar, Emma K Lendy, Bridget L Kaiser, Shaoyou Chu, Emily R Mason, Bruce T Lamb, Alan D Palkowitz, Timothy I Richardson · 2025
Read Identification of PLCG2 activators for the treatment of Alzheimer’s disease by Brent Clayton, Steven M Massey, Daniel E Beck, Karson S Putt, Tada Utsuki, Ramya Visvanathan, Andrew D Mesecar, Emma K Lendy, Bridget L Kaiser, Shaoyou Chu, Emily R Mason, Bruce T Lamb, Alan D Palkowitz, Timothy I Richardson (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712344.txt.
Description
Brent Clayton and co-authors hunt for small molecules that switch on a brain immune protein linked to lower Alzheimer's risk, in a 2025 study. A variant of the protein protects its carriers, who decline more slowly, while another variant raises risk. Turning the protein up with a drug could copy the protective effect.
The team screened for molecules that bind the full protein, then checked that they engage it inside cells and boost its enzyme action. Imaging tests measured how treated immune-like cells engulf debris, and related compounds were tuned for strength. Early animal work checked how the body handles the leads. The authors present the scaffolds as starting points for a new drug class.
Catalog record
| CREATOR | Brent Clayton, Steven M Massey, Daniel E Beck, Karson S Putt, Tada Utsuki, Ramya Visvanathan, Andrew D Mesecar, Emma K Lendy, Bridget L Kaiser, Shaoyou Chu, Emily R Mason, Bruce T Lamb, Alan D Palkowitz, Timothy I Richardson |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |